p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011)
- 25 October 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (12), 1843-1866
- https://doi.org/10.1517/13543776.2011.636737
Abstract
Since the first biological factor that neutralized tumor necrosis (TNF)-α was brought to the market, there has been a desperate search for small molecules with the same efficacy in therapy of inflammatory disorders. One of the most promising targets is p38α mitogen-activated protein (MAP) kinase. This enzyme is a key player in a vast number of inflammatory and autoimmune processes. Almost every international company doing research in drug discovery is or was involved in the development of compounds that inhibit p38α MAP kinase. Herein their patents and the corresponding publications are summarized. In the last few years, compounds have become more potent and more selective, for example, by induction of the so-called glycine flip. Furthermore, some companies are striving for selectivity with respect to isoforms. The increasing availability of rapid screening services, which include more than 400 kinases, has encouraged companies to reconsider traditional approaches. The most promising approach appears to be the development of linear binding molecules that feature a carbonyl oxygen that can enforce the glycine flip. Furthermore, recent projects increasingly target new fields of application, for example, pulmonary diseases. This might be the most important trend of the past few years.Keywords
This publication has 62 references indexed in Scilit:
- "Go upstream, young man": lessons learned from the p38 sagaAnnals Of The Rheumatic Diseases, 2009
- Inhibition of p38: Has the fat lady sung?Arthritis & Rheumatism, 2009
- Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibitionExpert Opinion on Drug Discovery, 2008
- Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibitionExpert Opinion on Drug Discovery, 2008
- A quantitative analysis of kinase inhibitor selectivityNature Biotechnology, 2008
- The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- Differential tissue expression and activation of p38 MAPK α, β, γ, and δ isoforms in rheumatoid arthritisArthritis & Rheumatism, 2006
- MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α ProteinCurrent Medicinal Chemistry, 2005
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- A protein kinase involved in the regulation of inflammatory cytokine biosynthesisNature, 1994